TCRT•Alaunos Therapeutics regained Nasdaq’s $2.5 million minimum stockholders’ equity requirement after completing a private placement on October 14, 2026. The delisting matter is closed, and the company’s common stock will continue trading on the Nasdaq Capital Market.
Nasdaq confirmed on October 22, 2026, that Alaunos Therapeutics had regained compliance with its $2.5 million minimum stockholders’ equity requirement. The delisting matter is closed, and the company’s common stock will continue trading on the Nasdaq Capital Market.
The compliance followed completion of a private placement financing on October 14. A Nasdaq Hearings Panel hearing scheduled for November 10 was canceled.
